A small single-center study that evaluated crizotinib as a monotherapy for patients with relapsed or refractory ALK+ ALCL, ALK+ DLBCL, and ALK+ PBL with 25, 1, and 1 patients, respectively, found a durable remission in almost 2/3 of the patients42. This evidence concerns the gene ALK and anaplastic large cell lymphoma.